Welcome Message
 
Our Company
 
Awards & Recognition
 
Corporate Governance
 
Management Council
Board of Directors
Reports of Insider Transactions
Committee Charters
Corporate Governance Guidelines
Additional Policies and Guidelines
Codes of Conduct
Articles of Incorporation (PDF)
Bylaws (PDF)
 
Corporate Compliance
 
Our Websites
 
Business Links

 

  » BMS.com Home » About Us » Corporate Governance » John E. Celentano
SEARCH INDEX
 





John E. Celentano

Senior Vice President, Strategy and Productivity Transformation

John E. CelentanoJohn Celentano is responsible for Corporate Strategy and the company’s Productivity Transformation Initiative.

"Our Productivity Transformation is a critical element of our strategy, and we've made significant progress to date. By removing unnecessary work, streamlining processes and improving efficiency we free up resources for re-investment in our future,” he says.

"A more competitive Bristol-Myers Squibb means that we will be able to bring more innovative products to market faster. Ultimately, the beneficiaries of our transformation are patients and customers, employees and shareholders."

John joined Bristol-Myers Squibb as a sales representative in 1982. He advanced through the Bristol-Myers Squibb ranks in sales, market research and marketing. In 2000, he became vice president and general manager, Northern Europe, and in 2002 was promoted to president of our operations in Latin America and Canada. Three years later, he was named president, Health Care Group, with responsibility for the Mead Johnson Nutritionals, ConvaTec and Medical Imaging divisions. John was appointed to his current role in March 2008.

John earned his bachelor’s degree from the University of Delaware in 1982 and an MBA from Drexel University in 1989. He is married and has three children.

June, 2008




[Top Page] [Search] [Index] [Contact] [Home]

Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Atripla is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.

 

SEARCH INDEX